Targeting CDK9 in Autoimmune Diseases: A New Approach to Inflammation Control

Abstract

Cyclin-dependent kinase 9 (CDK9), the kinase associated with positive transcription elongation factor b (P-TEFb), enhances transcription elongation by phosphorylating RNA polymerase II and transcription elongation factors. The critical function of P-TEFb is in mediating networks of transcription that are induced by cytokines. More specifically, P-TEFb is involved in STAT3 signaling induced by IL-6 and TNF-inducible NF-κB activation. Within these signaling cascades, the pathways become hyperactivated due to abnormal CDK9 activity, which in turn increases inflammation and causes tissue damage. Pharmacological research has recently made great strides, and new CDK9 inhibitors are being considered as potential treatment options for regulating abnormal inflammatory responses. The efficacy of these inhibitors in reducing inflammation and symptom severity has been demonstrated in preclinical studies of inflammatory diseases, including psoriasis, inflammatory bowel disease, rheumatoid arthritis, and atherosclerosis. The advancement of next-generation CDK9 inhibitors with improved selectivity and diminished off-target effects provides considerable promise for the treatment of many inflammatory disorders.